RNXT logo

RNXT
RenovoRx Inc

3,283
Mkt Cap
$36.5M
Volume
117,100.00
52W High
$1.45
52W Low
$0.7006
PE Ratio
-2.66
RNXT Fundamentals
Price
$0.8899
Prev Close
$0.8816
Open
$0.8809
50D MA
$0.9389
Beta
0.89
Avg. Volume
304,995.68
EPS (Annual)
-$0.3161
P/B
3.53
Rev/Employee
$66,058.82
$22.87
Loading...
Loading...
News
all
press releases
RenovoRx (RNXT) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
News Placeholder
More News
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +12.60%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +4.26% and -97.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -0.20% and +173.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +13.51% and -90.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of +11.11% and -0.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -175.00% and -90.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -17.70% and +83.68%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available